BioMedomics Announces Grants , Starting on June 19th, 2024,the world Sickle Cell Day, to Advance Sickle Cell Disease Testing in Sub-Saharan Africa

BioMedomics, the manufacturer of Sickle SCAN, the world’s first Point of Care rapid test for Sickle Cell Disease (SCD), is excited to announce a Request for Proposals (RFP) for Independent Research Grant aimed at advancing the testing and management of Sickle Cell Disease (SCD) in Sub-Saharan African countries.

The grant program will take the course of three years, starting on June 19th, 2024, the world’s Sickle Cell Disease day.

This initiative is part of BioMedomics’ ongoing commitment to improving global health through innovative diagnostics and education.
Sickle SCAN is a revolutionary diagnostic tool that enables rapid, convenient and accurate testing for SCD at the point of care, empowering healthcare professionals to swiftly diagnose Sickle Cell Disease and facilitating timely intervention and personalized patient care.

The program aims to increase Sickle Cell Disease awareness and facilitate the availability and affordability of POCT testing in Sub-Saharan Africa. BioMedomics will partner with local distributors to implement the program.

Frank Wang, PhD, founder and CEO of BioMedomics, expressed his commitment to patients, stating “As the world’s leading manufacturer of hemoglobin subtype antibodies, such as hemoglobin A, hemoglobin C, hemoglobin E, hemoglobin F and hemoglobin S, we will continue to develop more diagnostic products to fight against Sickle Cell Disease. ”

Xingzhou Liu, MD, MBA, VP and Chief Commercial Officer of BioMedomics, emphasized the company’s commitment to expanding access to Sickle SCAN. “Our goal is to reach more patients in need, and generate more attention for SCD patients, the families and the community”. Liu continued, ” In addition, we continue to develop broader and stronger distribution network to make Sickle SCAN readily available to a wider audience, ultimately improving the lives of individuals affected by SCD.”

For more information, please refer to Grant RFP.

BioMedomics, Inc. Recertified for ISO 13485

BioMedomics, Inc. is proud to announce that the BSI Group of America has accredited and recertified our ISO 13485:2016 certification.

The certification of compliance with ISO 13485:2016 recognizes that the policies, practices and procedures of our company ensure consistent quality in the product and services we provide our clients. With this certification, our clients can be confident that BioMedomics, Inc. is dedicated to maintaining the highest efficiency and responsiveness in achieving our ultimate goal – guaranteed client satisfaction.

BioMedomics, Inc. is certified as meeting the requirements of ISO 13485:2016 for the following activities:

The design, development and manufacture of in-vitro diagnostic medical devices used in the detection of hemoglobin disorders and/or adaptive immune responses including laboratory and point-of-care in-vitro diagnostic medical devices.

To maintain our certification, we will perform audits to ensure compliance and to assess initiatives for continued improvement. Our clients can be confident that BioMedomics, Inc. will continue to provide the high-quality products and services they have come to expect well into the future.

Sickle SCAN® Approved by Department of Health in Australia!

We are excited to announce that the Therapeutic Goods Administration, a branch of the Department of Health in the Australian Government, has given BioMedomics, Inc. authorization to sell and distribute our world-renown Sickle SCAN® rapid test in Australia! We have partnered with Helena Laboratories Australia Pty Ltd to assist with distributing our product to customers.

Sickle SCAN® is the world’s leading Sickle Cell Disease detection test, winning over competitor testing methods with:

  • Fastest test result of 5 minutes
  • Highest sensitivity/specificity (99%/99%)
  • Differentiates trait from disease
  • NO specialized training required
  • NO electricity required

For information or questions about Sickle SCAN®, please email info@biomedomics.com

To receive a quote and place an order, please email sales@biomedomics.com

Sickle SCAN® Approved by the Tanzania Medicines and Medical Devices Authority!

We are excited to announce that the Tanzania Medicines and Medical Devices Authority has given authorization to BioMedomics, Inc. to sell and distribute our world-renown Sickle SCAN® rapid test in Tanzania! We have partnered with Laborex Tanzania Limited to assist with distributing our product to customers.

Sickle SCAN® is the world’s leading Sickle Cell Disease detection test, winning over competitor testing methods with:

  • Fastest test result of 5 minutes
  • Highest sensitivity/specificity (99%/99%)
  • Differentiates trait from disease
  • NO specialized training required
  • NO electricity required

For information or questions about Sickle SCAN®, please email info@biomedomics.com

To receive a quote and place an order, please email sales@biomedomics.com

BioMedomics™ Participates in Free Sickle Cell Screening Events Using Sickle SCAN® Rapid Test During MEA Rugby Championship

Morrisville, NC, USA – BioMedomics, a leader in innovative clinical diagnostics products that address global healthcare needs, participated in several sickle cell screening events in Nigeria during the recent Middle East-Africa Rugby League Championship tournament. The company used its Sickle SCAN Rapid Test during the events to screen people for sickle cell disease and sickle cell trait at no charge.

“What a great event to help raise awareness of sickle cell in Nigeria,” said BioMedomics CEO Frank Wang. “And the Sickle SCAN test was ideal for these kind of events because it provides results so quickly and reliably. The more people can know their status, the better.”

BioMedomics’ distribution partner in Nigeria, Assene-Laborex, helped organize and sponsor the events, which were held from October 2 to October 5. Euracare, a leading healthcare provider in Nigeria, provided clinical experts to conduct the tests, and the Nigeria Rugby League Association (NRLA) was the event host.

In addition to a location outside the tournament venue, Teslim Balogun Stadium, screening events were also held at a Lagos Euracare Clinic, Toyibat Comprehensive High School, and the University of Lagos. Ade Adebisi, Vice Chairman and General Manager of NRLA and Sickle SCAN spokesperson, was on hand for some of the events to meet and sign autographs for event participants. Adebisi is a former professional rugby player who has sickle cell disease and works as an advocate for awareness, diagnosis, and treatment for the disease.

BioMedomics™ Introduces Nigerian Rugby Player Ade Adebisi as Brand Ambassador for Sickle SCAN® Product

Morrisville, NC, USA – BioMedomics, a leader in innovative clinical diagnostics products that address global healthcare needs, proudly announced a partnership today with Ade Adebisi, professional rugby player and Sickle Cell Disease advocate, to officially represent the company’s Sickle SCAN product. Sickle SCAN is the world’s first rapid test to help diagnose Sickle Cell Disease (SCD) and Sickle Cell Trait (SCT).

“We are proud and honored to have Ade Adebisi represent our Sickle SCAN brand,” said BioMedomics CEO Frank Wang. “He is a passionate advocate for raising awareness for SCD and as a living example of someone who has successfully managed the disease, he is a tremendous inspiration to everyone in the SCD community.”

Ade Adebisi is a British/Nigerian rugby league footballer who also played rugby for the British Rugby League Association (BARLA), with the London Skolars, the London Broncos, Hull FC, Doncaster Lakers, Featherstone Rovers and Whitehaven. He is currently the Vice Chairman and General Manager of the Nigeria Rugby League Association (NRLA). As perhaps the only rugby player with SCD to ever play professionally, Adebisi continues to strive against all odds and encourage young men and women across the globe who struggle with the disease.

“Awareness starts with knowing if you either have the disease, or if you carry the genetic trait,” said Adebisi. “Sickle SCAN is the world’s first diagnostic rapid test that can help determine both, and is a great solution for places like Nigeria and other sub-Saharan African countries where access to traditional laboratory testing isn’t very easy. I’m excited for the impact that Sickle SCAN can have on helping to improve people’s lives.”

What is Sickle Cell Disease?

Sickle Cell Disease (SCD) is an inherited blood disorder which often causes red blood cells to become sickle-shaped through the presence of the abnormal hemoglobin S variant. Highly rigid sickle-shaped blood may have difficulty passing through small blood vessels, blocking normal blood flow, damaging tissues, and ultimately leading to many of the complications of SCD. Additionally, cells containing mostly hemoglobin S live only about 16 days compared to 120 days for normal red blood cells.

To initiate life-saving therapies, early diagnosis of SCD is key. Preventing the disease starts with individuals knowing whether they are carriers, since the disease can only be passed on when both parents have the gene for SCD.

About BioMedomics Sickle SCAN:

BioMedomics Sickle SCAN is a multiplexed, qualitative, point-of-care immunoassay used for the rapid diagnosis of sickle cell disorders. The test is made up of three proprietary indicators which detect the presence of hemoglobins A, S, and C, allowing the user to rapidly distinguish between normal, carrier, and sickle cell disease samples.

Before Sickle SCAN, SCD and SCT diagnosis was only possible using complex lab equipment. In low-resource regions where the disease is responsible for 9% of all under-five infant mortality, infrastructure challenges make central lab testing impractical. Sickle SCAN helps overcome the diagnostic gap. Ideal for providing quick and accurate results at the point-of-care, the test requires no supporting equipment and can also be used preventatively for genetic counseling to reduce the incidence of sickle cell births.

About BioMedomics, Inc.

BioMedomics is a leader in innovative clinical diagnostics products that address global healthcare needs. Quick, easy, and affordable, the company’s point-of-care products are designed to be used anytime, anywhere, bringing accurate clinical results to the most vulnerable members of society. By placing immediate healthcare knowledge in the hands of individuals and their healthcare providers, the company aims to empower rapid treatment decisions which save and improve lives.

Founded in 2007, BioMedomics is a privately-held company located in Morrisville, North Carolina.

###

MEDIA CONTACTS

For BioMedomics:

Mr. Kent Lupino

klupino@biomedomics.com

+1 984 464 3571

 

For Ade Adebisi:

Ms. Shalom Lloyd

shalom@naturallytribalgroup.com

+44 (0) 776 8878 207